GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target

N I Herath; N Rocques; A Garancher; A Eychène; C Pouponnot

doi:10.1038/bcj.2013.67

journal article Jan 17, 2014

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target

N I Herath N Rocques A Garancher A Eychène C Pouponnot

Blood Cancer Journal Vol. 4 No. 1 pp. e175-e175 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/bcj.2013.67

Topics

No keywords indexed for this article. Browse by subject →

References

40

[1]

Genetic events in the pathogenesis of multiple myeloma

W.J. Chng, O. Glebov, P.L. Bergsagel et al.

Best Practice & Research Clinical Haematology 2007 10.1016/j.beha.2007.08.004

[2]

Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC . Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585–598. 10.1038/nrc2189

[3]

Kuehl WM, Bergsagel PL . Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175–187. 10.1038/nrc746

[4]

Morgan GJ, Walker BA, Davies FE . The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335–348. 10.1038/nrc3257

[5]

Chesi M, Bergsagel PL . Many multiple myelomas: making more of the molecular mayhem. Hematol Am Soc Hematol Educ Program 2011; 2011: 344–353. 10.1182/asheducation-2011.1.344

[6]

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood 2006; 108: 2020–2028. 10.1182/blood-2005-11-013458

[7]

Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210–2221. 10.1038/leu.2009.174

[8]

Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF . Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884–892. 10.1182/blood-2012-05-432203

[9]

Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011; 117: 4696–4700. 10.1182/blood-2010-10-300970

[10]

Rajkumar SV . Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479–491. 10.1038/nrclinonc.2011.63

[11]

Rajkumar SV . Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 225–235. 10.1002/ajh.23390

[12]

Avet-Loiseau H, Malard F, Campion L, Magrangeas F, Sebban C, Lioure B et al. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood 2011; 117: 2009–2011. 10.1182/blood-2010-07-295105

[13]

Eychene A, Rocques N, Pouponnot C . A new MAFia in cancer. Nat Rev Cancer 2008; 8: 683–693. 10.1038/nrc2460

[14]

Pouponnot C, Sii-Felice K, Hmitou I, Rocques N, Lecoin L, Druillennec S et al. Cell context reveals a dual role for Maf in oncogenesis. Oncogene 2006; 25: 1299–1310. 10.1038/sj.onc.1209171

[15]

Kataoka K, Shioda S, Yoshitomo-Nakagawa K, Handa H, Nishizawa M . Maf and Jun nuclear oncoproteins share downstream target genes for inducing cell transformation. J Biol Chem 2001; 276: 36849–36856. 10.1074/jbc.m102234200

[16]

Nishizawa M, Kataoka K, Vogt PK . MafA has strong cell transforming ability but is a weak transactivator. Oncogene 2003; 22: 7882–7890. 10.1038/sj.onc.1206526

[17]

Rocques N, Abou Zeid N, Sii-Felice K, Lecoin L, Felder-Schmittbuhl MP, Eychene A et al. GSK-3-mediated phosphorylation enhances Maf-transforming activity. Mol Cell 2007; 28: 584–597. 10.1016/j.molcel.2007.11.009

[18]

Han SI, Aramata S, Yasuda K, Kataoka K . MafA stability in pancreatic beta cells is regulated by glucose and is dependent on its constitutive phosphorylation at multiple sites by glycogen synthase kinase 3. Mol Cell Biol 2007; 27: 6593–6605. 10.1128/mcb.01573-06

[19]

Chesi M, Bergsagel PL, Shonukan OO, Martelli ML, Brents LA, Chen T et al. Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma. Blood 1998; 91: 4457–4463. 10.1182/blood.v91.12.4457.412k48_4457_4463

[20]

Hanamura I, Iida S, Akano Y, Hayami Y, Kato M, Miura K et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res 2001; 92: 638–644. 10.1111/j.1349-7006.2001.tb01142.x

[21]

Boersma-Vreugdenhil GR, Kuipers J, Van Stralen E, Peeters T, Michaux L, Hagemeijer A et al. The recurrent translocation t(14;20)(q32;q12) in multiple myeloma results in aberrant expression of MAFB: a molecular and genetic analysis of the chromosomal breakpoint. Br J Haematol 2004; 126: 355–363. 10.1111/j.1365-2141.2004.05050.x

[22]

Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004; 5: 191–199. 10.1016/s1535-6108(04)00019-4

[23]

Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011; 117: 2396–2404. 10.1182/blood-2010-04-278788

[24]

Suzuki A, Iida S, Kato-Uranishi M, Tajima E, Zhan F, Hanamura I et al. ARK5 is transcriptionally regulated by the Large-MAF family and mediates IGF-1-induced cell invasion in multiple myeloma: ARK5 as a new molecular determinant of malignant multiple myeloma. Oncogene 2005; 24: 6936–6944. 10.1038/sj.onc.1208844

[25]

Morito N, Yoh K, Fujioka Y, Nakano T, Shimohata H, Hashimoto Y et al. Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human. Cancer Res 2006; 66: 812–819. 10.1158/0008-5472.can-05-2154

[26]

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

Timothy R. Peterson, Mathieu Laplante, Carson C. Thoreen et al.

Cell 2009 10.1016/j.cell.2009.03.046

[27]

van Stralen E, van de Wetering M, Agnelli L, Neri A, Clevers HC, Bast BJ . Identification of primary MAFB target genes in multiple myeloma. Exp Hematol 2009; 37: 78–86. 10.1016/j.exphem.2008.08.006

[28]

Morito N, Yoh K, Maeda A, Nakano T, Fujita A, Kusakabe M et al. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23). Cancer Res 2011; 71: 339–348. 10.1158/0008-5472.can-10-1057

[29]

Kuehl WM, Bergsagel PL . Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012; 122: 3456–3463. 10.1172/jci61188

[30]

Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K . Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012; 9: 135–143. 10.1038/nrclinonc.2012.15

[31]

Benkhelifa S, Provot S, Lecoq O, Pouponnot C, Calothy G, Felder-Schmittbuhl MP . mafA, a novel member of the maf proto-oncogene family, displays developmental regulation and mitogenic capacity in avian neuroretina cells. Oncogene 1998; 17: 247–254. 10.1038/sj.onc.1201898

[32]

Patel S, Woodgett J . Glycogen synthase kinase-3 and cancer: good cop, bad cop? Cancer Cell 2008; 14: 351–353. 10.1016/j.ccr.2008.10.013

[33]

Billadeau DD . Primers on molecular pathways. The glycogen synthase kinase-3beta. Pancreatology 2007; 7: 398–402. 10.1159/000108955

[34]

Ougolkov AV, Billadeau DD . Targeting GSK-3: a promising approach for cancer therapy? Future Oncol 2006; 2: 91–100. 10.2217/14796694.2.1.91

[35]

Wang Z, Smith KS, Murphy M, Piloto O, Somervaille TC, Cleary ML . Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008; 455: 1205–1209. 10.1038/nature07284

[36]

Wang Z, Iwasaki M, Ficara F, Lin C, Matheny C, Wong SH et al. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010; 17: 597–608. 10.1016/j.ccr.2010.04.024

[37]

Busino L, Millman SE, Scotto L, Kyratsous CA, Basrur V, O'Connor O et al. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 2012; 14: 375–385. 10.1038/ncb2463

[38]

Geng F, Wenzel S, Tansey WP . Ubiquitin and proteasomes in transcription. Annu Rev Biochem 2012; 81: 177–201. 10.1146/annurev-biochem-052110-120012

[39]

Doble BW, Woodgett JR . GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116: 1175–1186. 10.1242/jcs.00384

[40]

Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?

Xiaohua Li, Richard S Jope

Neuropsychopharmacology 2010 10.1038/npp.2010.105

Metrics

52

Citations

40

References

Details

Published: Jan 17, 2014
Vol/Issue: 4(1)
Pages: e175-e175
License: View

Authors

Cite This Article

N I Herath, N Rocques, A Garancher, et al. (2014). GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer Journal, 4(1), e175-e175. https://doi.org/10.1038/bcj.2013.67

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target

You May Also Like